Enlivex Therapeutics is trading at $2.42 (8% up) in pre-market following a $400 million private placement agreement with a single institutional investor.
- The deal is priced at a premium of $5.00 per share and allows for subscriptions in U.S. dollars, stablecoins, or RAIN tokens.
- The stock is seeing a modest recovery after a 47% plunge in the previous session, where the price fell from $4.26 to $2.24.
- The unique structure of the investment, involving digital assets, is drawing renewed market attention to the biotech firm.